Fig. 3
- ID
- ZDB-FIG-231221-52
- Publication
- Zhong et al., 2023 - Zebrafish functional xenograft vasculature platform identifies PF-502 as a durable vasculature normalization drug
- Other Figures
- All Figure Page
- Back to All Figure Page
Parallel testing of potential tumor vascular normalization chemicals using zFXVP-VAST-Imaris platform (A) Schematic diagram showing the process of screening tumor vascular normalization drugs using zFXVP-VAST-Imaris platform. The white arrow indicates imaged xenografts which are magnified on the right. (B) Statistics of vascular density, the ratio of blood-perfused vessels and vascular branch points of tumor xenografts treated or not treated with the 11 chemical candidates. Quantitative numbers are summarized below. Data are expressed as means +SEM. ????p < 0.0001, ??p < 0.01, ?p < 0.05. Student?s t test. (C) The curves represent the percentage of normal development in zebrafish after 5 days of continuous treatment with candidate compounds (1 ?M) or an equivalent amount of solvent. n = 20. (D) Maximum intensity projection of the tumor vasculature in the xenografts with or without PF-502 (S2743) treatment on 3 dpi gata1:dsRed/kdrl:EGFP double transgenic zebrafish showing flowing red blood cells (white arrows) in neo-vessels. Areas in dotted boxes are magnified right. Scale bars: 50 ?m. (E) Vessel diameters, blood vessel densities and percentages of functional vessels in tumor xenografts with or without PF-502 treatment, Data are expressed as means +SEM. ????p < 0.0001, ??p < 0.01. Student?s t test. |